HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Analysis Of Non-Traditionally Preserved Cosmetics Indicates Likely Contamination Source

This article was originally published in The Rose Sheet

Executive Summary

The agency’s survey of eye-area cosmetics marketed as free of traditional preservatives doesn’t raise any obvious red flags. However, it does point to a possible contamination source and suggests “the limits of preservative activity in cosmetics.”

You may also be interested in...



European Guidelines Now In Effect For ‘Free From,’ ‘Hypoallergenic’ Cosmetic Claims

According to Cosmetics Europe, at least “several” EU Member States are expected to be monitoring the marketplace for compliance with guidance developed by a European Commission working group, key aspects of which – concerning “free from” and “hypoallergenic” claims – went into effect 1 July.

2018 In Review: Cosmetics Industry Mobilizes To Stop Preservatives Die-Off

Trade group Cosmetics Europe launched an education and advocacy campaign in 2018 to address industry’s shrinking preservative palette, which many believe has reached “crisis proportions." Stateside, 2018 saw growing movement in the development and use of alternative preservative systems, while Cosmetic Ingredient Review activity accelerated around conventional go-tos.

FDA Shopping For 3D Tissue Bioprinter, Cosmetic Contamination Testing Services

Recent procurement activities show an agency increasingly focused on cosmetics’ safety vis-a-vis microbial threats and, in the case of talc-containing products, asbestos. Meanwhile, FDA seeks a 3D bioprinter to use in organ toxicity studies as an alternative to traditional animal models.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121732

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel